Former head of Operation Warp Speed loses board seat over sexual harassment claims

GlaxoSmithKline’s board of directors announced today that it terminated Moncef Slaoui as the chair of the Galvani board of directors.

Slaoui, who served as the head of Operation Warp Speed — the Trump administration’s program to accelerate COVID-19 vaccine development — was terminated effective immediately, according to a news release from GSK, the majority shareholder of Galvani Bioelectronics.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0